|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Newer Drugs May Cut Stroke, Heart Attack Risk
10/19/2005 5:12:57 PM
Patients with high blood pressure taking a mixture of newer drugs may cut their risk of stroke by 25 percent and dangerous heart complications by 15 percent compared with those on older pills, according to a large study released on Tuesday.
The advantage is so dramatic that many patients on the older regime of a beta blocker drug and a diuretic should halt their treatment and begin taking the newer combination, which includes Pfizer Inc.'s .drug Norvasc and CV Therapeutics' Aceon, researchers said.
The 20,000-person, Pfizer-funded study was halted early, last November, after researchers found the drugs were so much better than conventional treatment with a beta-blocker and a diuretic. Full results were presented at the American College of Cardiology meeting in Orlando, Florida, which ends on March 9.
The newer drugs are Norvasc, known generically as amlodipine, a calcium channel blocker and perindopril, an ACE inhibitor, sold by CV Therapeutics and Solvay Pharmaceuticals as Aceon.
They were tested in the study against AstraZeneca's atenolol, a beta blocker that has been off patent for several years, and a diuretic pill.
|
|
|
|
|
|
|
|
|
|
|